Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Immunon Inc (IMNN) is a clinical-stage biotechnology pioneer developing DNA-based immunotherapies through its proprietary non-viral platform. This page serves as the definitive source for verified company updates, including clinical trial progress, regulatory milestones, and research breakthroughs.
Investors and researchers will find timely updates on key programs like the IMNN-001 ovarian cancer therapy (Phase II completed) and IMNN-101 COVID-19 booster candidate. Our curated news feed covers essential developments including partnership announcements, intellectual property updates, and peer-reviewed study publications.
Content is organized to highlight material events across three core areas: Clinical Trial Advancements, Regulatory Pathway Updates, and Technology Platform Innovations. Each update is vetted for relevance to stakeholders monitoring the company's progress in immuno-oncology and infectious disease applications.
Bookmark this page for structured access to Immunon's official communications, including SEC filings analysis and conference presentation summaries. Check regularly for developments in DNA-based therapeutic approaches that aim to redefine cancer treatment and vaccine development paradigms.
IMUNON (NASDAQ: IMNN) has secured a private placement offering priced at-the-market, raising $3.25 million initially through the sale of 7,222,223 shares of common stock (or pre-funded warrants) at $0.45 per share. The deal includes short-term warrants to purchase up to 14,444,446 additional shares, which could generate up to $6.5 million in additional proceeds if fully exercised.
The warrants will be exercisable at $0.45 per share upon stockholder approval and will expire after three years. The offering, expected to close around May 27, 2025, is being managed by H.C. Wainwright & Co. as exclusive placement agent, with Brookline Capital Markets as financial advisor. The company plans to use the proceeds for working capital and general corporate purposes.
IMUNON (NASDAQ: IMNN) has announced groundbreaking results from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study demonstrated a 13-month increase in median overall survival (46 vs. 33 months) and a 3-month improvement in progression-free survival (14.9 vs. 11.9 months) compared to standard care.
Notably, patients receiving PARP inhibitors alongside IMNN-001 showed exceptional results, with median overall survival not yet reached after 5+ years versus 37 months in the control group. The therapy was well-tolerated with no serious immune-related adverse events. Based on these promising results, IMUNON has initiated its pivotal Phase 3 OVATION 3 Study at two sites.
The findings will be presented at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology.IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, has announced the withdrawal of its Form S-1 Registration Statement (No. 333-286403) with the SEC. The registration statement, originally filed on April 4, 2025, was withdrawn as the company has decided not to proceed with the planned public offering at this time. The statement had not been declared effective by the SEC, and no securities were sold in connection with the offering.
IMUNON (NASDAQ: IMNN) has scheduled a conference call for Monday, May 12, 2025, at 11:00 a.m. ET to discuss its first quarter 2025 financial results and provide updates on its clinical development programs. The company will specifically focus on the progress of IMNN-001, their DNA-based interleukin-12 immunotherapy, including developments toward initiating a Phase 3 clinical trial in advanced ovarian cancer.
Participants can join via phone at 833-816-1132 (North America) or 412-317-0711 (International). The call recording will be available until May 26, 2025, with replay access code 2322959. A webcast will also be accessible and archived online for 90 days.
IMUNON (NASDAQ: IMNN) announced that new survival data from its Phase 2 OVATION 2 Study of IMNN-001 for treating newly diagnosed advanced ovarian cancer will be presented at the 2025 ASCO Annual Meeting (May 30-June 3, Chicago).
The company recently aligned with the FDA on the protocol for the Phase 3 OVATION 3 clinical trial and has begun trial site activation. IMNN-001, based on their TheraPlas® technology platform, is an IL-12 DNA plasmid vector in a nanoparticle delivery system that enables local production of IL-12 protein in the tumor environment.
IMNN-001 is notable as the first and only IL-12 immunotherapy showing clinical effectiveness, including survival benefits, in frontline treatment for advanced (Stage III/IV) ovarian cancer patients. The presentation at ASCO will be delivered by Dr. Premal H. Thaker from Washington University School of Medicine.
IMUNON (NASDAQ: IMNN) has received FDA alignment for its Phase 3 OVATION 3 pivotal trial protocol for IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer. The trial will evaluate IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy versus standard care.
The study's primary endpoint is overall survival, with secondary endpoints including surgical response score, chemotherapy response score, clinical response, and time to second-line treatment. Recent Phase 2 OVATION 2 data showed IMNN-001 plus NACT improved median overall survival to 46 months, surpassing standard-of-care by 13 months, with an excellent safety profile.
The Phase 3 trial will randomize participants 1:1, focusing on women with newly diagnosed advanced ovarian cancer (stage 3 or 4) eligible for neoadjuvant therapy. HRD-positive participants will receive PARP inhibitors as maintenance therapy.
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
